

Jeska De Vries-Bouwstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5088191/publications.pdf>

Version: 2024-02-01

73
papers

1,063
citations

430754

18
h-index

477173

29
g-index

73
all docs

73
docs citations

73
times ranked

1708
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical Therapy in Systemic Sclerosis: The Patient Perspective. <i>Arthritis Care and Research</i> , 2023, 75, 145-151.	1.5	2
2	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
3	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
4	Gastrointestinal symptom severity and progression in systemic sclerosis. <i>Rheumatology</i> , 2022, , .	0.9	2
5	The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 845359.	1.1	5
6	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	0.9	2
7	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
8	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
9	Evaluation of Left Cardiac Chamber Function with Cardiac Magnetic Resonance and Association with Outcome in Patients with Systemic Sclerosis. <i>Rheumatology</i> , 2022, , .	0.9	3
10	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.4	4
11	Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 402-409.	1.0	6
12	Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2021, 73, 722-731.	1.5	4
13	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.5	20
14	Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 96-101.	1.0	1
15	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
16	Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. <i>Rheumatology</i> , 2021, 60, 3646-3655.	0.9	22
17	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. <i>BMJ Open</i> , 2021, 11, e044483.	0.8	11
18	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.5	24

#	ARTICLE	IF	CITATIONS
19	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2338-2347.	2.9	14
20	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	1.3	27
21	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. <i>RMD Open</i> , 2021, 7, e001524.	1.8	3
22	Anti-CCP1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single-centre, cross-sectional study. <i>British Journal of Dermatology</i> , 2021, 185, 657-658.	1.4	0
23	Physical therapy in patients with systemic sclerosis: physical therapists' perspectives on current delivery and educational needs. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-8.	0.6	2
24	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2020, 47, 249-254.	1.0	23
25	Living with systemic sclerosis: exploring its impact on caregivers. <i>Disability and Rehabilitation</i> , 2020, 42, 1632-1633.	0.9	3
26	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. <i>Rheumatology</i> , 2020, 59, 1226-1232.	0.9	11
27	Quality of life and strain among caregivers of patients with systemic sclerosis. <i>Disability and Rehabilitation</i> , 2020, 42, 1783-1784.	0.9	2
28	Pulmonary veno-occlusive disease in a patient with recently diagnosed systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, NP1-NP4.	1.0	0
29	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 140-148.	1.6	13
30	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	0.9	13
31	From "being at war" to "getting back on your feet": A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 202-209.	1.0	2
32	Botulinum toxin type A in the treatment of Raynaud's phenomenon. <i>Dermatologic Therapy</i> , 2020, 33, e14182.	0.8	6
33	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. <i>Arthritis Care and Research</i> , 2020, , .	1.5	13
34	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.5	32
35	Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I Positive Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1897-1904.	2.9	18
36	Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study. <i>Musculoskeletal Care</i> , 2020, 18, 177-186.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2020, 39, 1543-1549.	1.0	4
38	Long noncoding RNA H19X is a key mediator of TGF- β -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 4888-4905.	3.9	52
39	Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 25-28.	0.4	2
40	Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening. <i>Journal of Rheumatology</i> , 2019, 46, 1244.1-1245.	1.0	0
41	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	5.8	100
42	E070 Shared decision-making in progressive diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2019, 58, .	0.9	3
43	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. <i>Rheumatology</i> , 2019, 58, 730-732.	0.9	9
44	OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1100.	2.2	22
45	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. <i>Journal of Rheumatology</i> , 2019, 46, 405-415.	1.0	17
46	Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 4521.	1.6	29
47	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	1.8	91
48	PARE0019 LIVING WITH SYSTEMIC SCLEROSIS: EXPLORING ITS IMPACT ON CAREGIVERS: A QUALITATIVE STUDY. , 2019, , .		0
49	SAT0269 THE IMPACT OF SMOKING ON NAILFOLD MICROANGIOPATHY AND AUTOANTIBODY STATUS IN MALE AND FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
50	The effect and safety of exercise therapy in patients with systemic sclerosis: a systematic review. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz044.	0.3	32
51	Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference. <i>Clinical Rheumatology</i> , 2019, 38, 1007-1015.	1.0	16
52	Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 82-87.	0.4	2
53	Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 826-835.	0.3	37
54	Physical activity in patients with systemic sclerosis. <i>Rheumatology International</i> , 2018, 38, 443-453.	1.5	16

#	ARTICLE	IF	CITATIONS
55	SAT0473â€¦Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis. , 2018, , .		0
56	ECG derived ventricular gradient exceeds echocardiography in the early detection of pulmonary hypertension in scleroderma patients. International Journal of Cardiology, 2018, 273, 203-206.	0.8	10
57	A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. BMJ Open, 2018, 8, e020479.	0.8	21
58	THU0655â€¦Patientsâ€™™ evaluation of dutch health care in systemic sclerosis: unmet needs and preferences. , 2018, , .		0
59	To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 109-117.	0.4	4
60	Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. Rheumatology, 2017, 56, kev402.	0.9	31
61	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. Arthritis and Rheumatology, 2017, 69, 1337-1338.	2.9	9
62	Auto-antibodies and cancer in systemic sclerosis. Autoimmunity Reviews, 2017, 16, 883-884.	2.5	7
63	Rituximab in early systemic sclerosis. RMD Open, 2017, 3, e000384.	1.8	47
64	05.11â€¦Antisense long noncoding rnas are deregulated in skin tissue of ssc patients. , 2017, , .		0
65	P5410Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis. European Heart Journal, 2017, 38, .	1.0	0
66	Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. Rheumatology, 2016, 55, kev342.	0.9	4
67	Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis. RMD Open, 2016, 2, e000159.	1.8	40
68	SAT0231â€¦Physical Activity in Patients with Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 752.1-752.	0.5	1
69	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	2.9	46
70	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new <i>locus</i> in the IL-12 pathway. Annals of the Rheumatic Diseases, 2016, 75, 1521-1526.	0.5	41
71	A prediction model for progressive disease in systemic sclerosis. RMD Open, 2015, 1, e000113.	1.8	5
72	Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 1747-53.	1.0	21

#	ARTICLE	IF	CITATIONS
73	Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). Arthritis Care and Research, 0, , .	1.5	1